Current and potential imaging applications of ferumoxytol for magnetic resonance imaging

Gerda B. Toth; Csanad G. Varallyay; Andrea Horvath; Mustafa R. Bashir; Peter L. Choyke; Heike E. Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S. Vasanawala; Prakash Ambady; Ramon Barajas; Justin S. Cetas; Jeremy Ciporen; Thomas J. DeLoughery; Nancy D. Doolittle; Rongwei Fu; John Grinstead; Alexander R. Guimaraes; Bronwyn E. Hamilton; Xin Li; Heather L. McConnell; Leslie L. Muldoon; Gary Nesbit; Joao P. Netto; David Petterson; William D. Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A. Neuwelt

doi:10.1016/j.kint.2016.12.037

Current and potential imaging applications of ferumoxytol for magnetic resonance imaging

Gerda B. Toth, Csanad G. Varallyay, Andrea Horvath, Mustafa R. Bashir, Peter L. Choyke, Heike E. Daldrup-Link, Edit Dosa, John Paul Finn, Seymur Gahramanov, Mukesh Harisinghani, Iain Macdougall, Alexander Neuwelt, Shreyas S. Vasanawala, Prakash Ambady, Ramon Barajas, Justin S. Cetas, Jeremy Ciporen, Thomas J. DeLoughery, Nancy D. Doolittle, Rongwei FuJohn Grinstead, Alexander R. Guimaraes, Bronwyn E. Hamilton, Xin Li, Heather L. McConnell, Leslie L. Muldoon, Gary Nesbit, Joao P. Netto, David Petterson, William D. Rooney, Daniel Schwartz, Laszlo Szidonya, Edward A. Neuwelt

Research output: Contribution to journal › Review article › peer-review

223 Scopus citations

Abstract

Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.

Original language	English (US)
Pages (from-to)	47-66
Number of pages	20
Journal	Kidney International
Volume	92
Issue number	1
DOIs	https://doi.org/10.1016/j.kint.2016.12.037
State	Published - Jul 2017

Keywords

chronic kidney disease
magnetic resonance imaging
nephrotoxicity

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.kint.2016.12.037

Cite this

Toth, G. B., Varallyay, C. G., Horvath, A., Bashir, M. R., Choyke, P. L., Daldrup-Link, H. E., Dosa, E., Finn, J. P., Gahramanov, S., Harisinghani, M., Macdougall, I., Neuwelt, A., Vasanawala, S. S., Ambady, P., Barajas, R., Cetas, J. S., Ciporen, J., DeLoughery, T. J., Doolittle, N. D., ... Neuwelt, E. A. (2017). Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney International, 92(1), 47-66. https://doi.org/10.1016/j.kint.2016.12.037

Toth, GB, Varallyay, CG, Horvath, A, Bashir, MR, Choyke, PL, Daldrup-Link, HE, Dosa, E, Finn, JP, Gahramanov, S, Harisinghani, M, Macdougall, I, Neuwelt, A, Vasanawala, SS, Ambady, P, Barajas, R, Cetas, JS, Ciporen, J, DeLoughery, TJ, Doolittle, ND, Fu, R, Grinstead, J, Guimaraes, AR , Hamilton, BE , Li, X, McConnell, HL, Muldoon, LL, Nesbit, G, Netto, JP, Petterson, D , Rooney, WD, Schwartz, D, Szidonya, L & Neuwelt, EA 2017, 'Current and potential imaging applications of ferumoxytol for magnetic resonance imaging', Kidney International, vol. 92, no. 1, pp. 47-66. https://doi.org/10.1016/j.kint.2016.12.037

@article{aab0285aeaef4d2195ac485d7604520e,

title = "Current and potential imaging applications of ferumoxytol for magnetic resonance imaging",

abstract = "Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.",

keywords = "chronic kidney disease, magnetic resonance imaging, nephrotoxicity",

author = "Toth, {Gerda B.} and Varallyay, {Csanad G.} and Andrea Horvath and Bashir, {Mustafa R.} and Choyke, {Peter L.} and Daldrup-Link, {Heike E.} and Edit Dosa and Finn, {John Paul} and Seymur Gahramanov and Mukesh Harisinghani and Iain Macdougall and Alexander Neuwelt and Vasanawala, {Shreyas S.} and Prakash Ambady and Ramon Barajas and Cetas, {Justin S.} and Jeremy Ciporen and DeLoughery, {Thomas J.} and Doolittle, {Nancy D.} and Rongwei Fu and John Grinstead and Guimaraes, {Alexander R.} and Hamilton, {Bronwyn E.} and Xin Li and McConnell, {Heather L.} and Muldoon, {Leslie L.} and Gary Nesbit and Netto, {Joao P.} and David Petterson and Rooney, {William D.} and Daniel Schwartz and Laszlo Szidonya and Neuwelt, {Edward A.}",

note = "Publisher Copyright: {\textcopyright} 2017",

year = "2017",

month = jul,

doi = "10.1016/j.kint.2016.12.037",

language = "English (US)",

volume = "92",

pages = "47--66",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Current and potential imaging applications of ferumoxytol for magnetic resonance imaging

AU - Toth, Gerda B.

AU - Varallyay, Csanad G.

AU - Horvath, Andrea

AU - Bashir, Mustafa R.

AU - Choyke, Peter L.

AU - Daldrup-Link, Heike E.

AU - Dosa, Edit

AU - Finn, John Paul

AU - Gahramanov, Seymur

AU - Harisinghani, Mukesh

AU - Macdougall, Iain

AU - Neuwelt, Alexander

AU - Vasanawala, Shreyas S.

AU - Ambady, Prakash

AU - Barajas, Ramon

AU - Cetas, Justin S.

AU - Ciporen, Jeremy

AU - DeLoughery, Thomas J.

AU - Doolittle, Nancy D.

AU - Fu, Rongwei

AU - Grinstead, John

AU - Guimaraes, Alexander R.

AU - Hamilton, Bronwyn E.

AU - Li, Xin

AU - McConnell, Heather L.

AU - Muldoon, Leslie L.

AU - Nesbit, Gary

AU - Netto, Joao P.

AU - Petterson, David

AU - Rooney, William D.

AU - Schwartz, Daniel

AU - Szidonya, Laszlo

AU - Neuwelt, Edward A.

PY - 2017/7

Y1 - 2017/7

N2 - Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.

AB - Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.

KW - chronic kidney disease

KW - magnetic resonance imaging

KW - nephrotoxicity

UR - http://www.scopus.com/inward/record.url?scp=85018617541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018617541&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2016.12.037

DO - 10.1016/j.kint.2016.12.037

M3 - Review article

C2 - 28434822

AN - SCOPUS:85018617541

SN - 0085-2538

VL - 92

SP - 47

EP - 66

JO - Kidney International

JF - Kidney International

IS - 1

ER -

Current and potential imaging applications of ferumoxytol for magnetic resonance imaging

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this